Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Summary
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Summary
Net income for Q3 rose to $12.3 million from an adjusted net income last year of $5.3 million helped by a tax benefit change.The following is a summary of the Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript:
以下是Organogenesis Holdings, Inc. (ORGO) 2024年第三季度業績會簡報：
Financial Performance:
財務表現:
Organogenesis reported Q3 revenue of $115.2 million, a 6% increase from last year, exceeding expectations.
Gross profit for Q3 was $88 million, representing 76.7% of net revenue. Operating income was $6.2 million, a decrease of 22% from the previous year.
Net income for Q3 rose to $12.3 million from an adjusted net income last year of $5.3 million helped by a tax benefit change.
Organogenesis報告第三季度營業收入11520萬美元，比去年增長6%，超出預期。
第三季度毛利潤爲8800萬美元，佔淨營業收入的76.7%。運營收入爲620萬美元，比去年同期下降22%。
第三季度淨利潤從去年調整後的530萬美元增至1230萬美元，受稅收利益變更所幫助。
Business Progress:
業務進展：
Organogenesis has made significant progress on its RENEW biologic intra-articular injection for knee osteoarthritis with favorable outcomes from phases of clinical trials.
Published strong data for NEUSHEAL in the Journal of Wound Care, showcasing its efficacy in wound closure.
Announced the initiation of the PREPARE study, evaluating PurePly AM in chronic DFUs, which informs their strategic growth.
Completed a $100 million private placement of Series A convertible preferred stock to strengthen its financial position and support strategic initiatives.
Organogenesis在其RENEW生物內關節注射治療膝關節骨關節炎方面取得了重要進展，臨床試驗階段取得了良好的成果。
在《Wound Care雜誌》上發佈了NEUSHEAL的強大數據，展示了其在傷口閉合方面的功效。
宣佈啓動PREPARE研究，評估PurePly Am在慢性腳底潰瘍中的應用，這對公司戰略增長有重要意義。
完成10000萬美元的A轉換優先股的私募股份，以加強其財務狀況，並支持戰略舉措。
Opportunities:
機會：
RENEW, once approved, will address a large unmet clinical need in pain management for over 30 million Americans, offering a significant market opportunity.
Potential positive changes in Medicare coverage and payment for skin substitutes could benefit the company's wound care products.
一旦獲批，RENEW將滿足3000萬美國人在疼痛管理方面的巨大臨床需求，爲公司提供巨大的市場機遇。
醫療保險涵蓋範圍和皮膚替代品報銷支付的潛在積極變化可能有利於公司的傷口護理產品。
Risks:
風險：
Potential near-term market disruption expected due to the final ruling of Local Coverage Determinations (LCDs), impacting the fourth quarter's performance.
由於本地覆蓋決定的最終裁定預計會帶來潛在的近期市場擾動，影響第四季度的業績。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
